2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12B.02 Real-World Treatment Patterns and Effectiveness in Patients with ALK+ Advanced NSCLC Treated with 1L ALK TKIs

EP.12B.02 Real-World Treatment Patterns and Effectiveness in Patients with ALK+ Advanced NSCLC Treated with 1L ALK TKIs

Pdf Summary

The study presented at the World Conference on Lung Cancer (WCLC) 2024 in San Diego, USA, focused on the real-world treatment patterns and effectiveness of first-line (1L) therapies in patients with advanced anaplastic lymphoma kinase-positive (ALK) non-small cell lung cancer (NSCLC). This cancer type constitutes approximately 4-5% of all NSCLC cases. The study, utilizing data from the US Flatiron electronic medical record database, included 832 patients prescribed one of the available ALK tyrosine kinase inhibitors (TKIs): alectinib, brigatinib, crizotinib, or lorlatinib.<br /><br />First-line alectinib and brigatinib demonstrated comparable outcomes in terms of real-world time to treatment discontinuation (rwTTD) and real-world time to next treatment (rwTTNT), both outperforming crizotinib, an earlier treatment option. Specifically, adjusted rwTTD and rwTTNT were more favorable for 1L alectinib and brigatinib compared to crizotinib, with hazard ratios indicating significantly reduced risk of treatment discontinuation for both alectinib (HR 0.304) and brigatinib (HR 0.357) versus crizotinib. The study verified that alectinib and brigatinib improve the median duration before treatment change or discontinuation compared to crizotinib.<br /><br />However, the research acknowledged certain limitations, such as potential biases due to small sample sizes for some cohorts and incomplete data. Additionally, most data were derived from community-based healthcare practices, possibly limiting the applicability of findings across diverse medical settings.<br /><br />Overall, the study supports clinical trial findings, recommending 1L alectinib and brigatinib as preferable choices over crizotinib for advanced ALK NSCLC due to improved patient outcomes. The study was funded by Takeda Development Center Americas, Inc., with involvement from contributors affiliated with various research institutions and Takeda Pharmaceuticals.

Asset Subtitle

Yin Wan

Meta Tag

Speaker Yin Wan

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

World Conference on Lung Cancer

first-line therapies

ALK-positive NSCLC

real-world treatment patterns

tyrosine kinase inhibitors

alectinib

brigatinib

crizotinib

real-world time to treatment

Takeda Pharmaceuticals